ArticleMolecular biology reports2026
Dysregulation of IL-37/SIGIRR Axis in De Novo acute myeloid leukemia patients: association with treatment response.
Article in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundInterleukin-37 (IL-37) is an anti-inflammatory cytokine with emerging roles in immune regulation and tumor biology. Its functional interaction with the single immunoglobulin IL-1-related receptor (SIGIRR) has been implicated in modulation of inflammatory signaling pathways that may influence leukemogenesis. However, the clinical significance of the IL-37/SIGIRR axis in acute myeloid leukemia (AML) remains insufficiently explored. The present study explored their potential associations with clinical characteristics, molecular mutations and treatment outcomes to determine their utility as potential prognostic biomarkers in the studied population. METHODS AND
resultsThis study enrolled 50 newly diagnosed adult patients with AML and 50 age and sex matched healthy controls. Expression levels of IL-37 and SIGIRR mRNA were quantified using reverse transcription quantitative polymerase chain reaction (RTqPCR). Both IL-37 and SIGIRR mRNA expression levels were significantly downregulated in patients with acute myeloid leukemia (AML) compared to healthy controls (p = 0.011 and p < 0.001, respectively). Notably, patients with refractory disease exhibited significantly lower expression levels of both markers compared to those who achieved complete remission (p = 0.006 and p < 0.001, respectively).
conclusionsThe present findings indicate that down-regulation of IL-37 and its receptor SIGIRR is associated with poor therapeutic response in AML. These results suggest that the IL-37/SIGIRR axis represents a potential prognostic biomarker and may contribute to immune-mediated mechanisms involved in AML progression. Further large-scale studies are warranted to validate these findings and to explore the potential of targeting this pathway as a novel immunomodulatory therapeutic strategy in AML.
Indexed as
Identifiers
42377398What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.